<DOC>
	<DOCNO>NCT01534052</DOCNO>
	<brief_summary>A study ass safety continue administration MDV3100 subject Prostate Cancer already undergone treatment MDV3100 show benefit .</brief_summary>
	<brief_title>A Study Assess Safety Continued Administration MDV3100 Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure MDV3100</brief_title>
	<detailed_description>This multi-center extension study subject prostate cancer complete MDV3100 treatment study ass long-term safety continue administration MDV3100 , judge investigator best interest subject . For study duration , subject castration-resistant prostate cancer ( CRPC ) maintain androgen deprivation Luteinizing Hormone Releasing Hormone ( LHRH ) agonist/antagonist unless underwent bilateral orchiectomy . Subjects discontinue study drug continue administration study drug deem subject 's best interest investigator base clinical assessment . Throughout study , safety tolerability assess record adverse event , monitor vital sign physical examination , safety laboratory evaluation , 12-lead electrocardiogram ( ECGs ) . Subjects safety follow-up visit 30 day last dose study drug .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has complete prior study MDV3100 , enrol extension study without interruption study drug No new clinically significant abnormality base upon physical examination , safety laboratory data , vital sign , ECG , clinical assessment note last visit conduct subject 's active MDV3100 study prior initiation study Male subject female spouses/partners childbearing potential must use highly effective contraception1 consist two form birth control ( one must barrier method ) start Screening continue throughout study period 3 month final study drug administration . Male subject must donate sperm start Screening throughout study period least 3 month final study drug administration . 1Highly effective contraception define : Established use oral , injected implant hormonal method contraception . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . Barrier method contraception : Condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal form/gel/film/ cream/suppository Subject agree participate another interventional study treatment Subject exclude participation follow apply : 1 . Subject history seizure condition may predispose seizure include , limited underlie brain injury , stroke , primary brain tumour , brain metastasis , alcoholism . 2 . Subject history loss consciousness transient ischemic attack within 12 month prior Day 1 complete preceding study . 3 . Use follow prohibited medication/therapies : Concomitant medication likely could cause clinically relevant drugtodrug interaction MDV3100 . Other ( MDV3100 ) androgenreceptor ( AR ) antagonists ( bicalutamide , flutamide , nilutamide ) . Investigational therapy MDV3100 investigational procedure kind .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Castration-Resistant Prostate Cancer ( CRPC )</keyword>
	<keyword>MDV3100</keyword>
	<keyword>Androgen receptor signal inhibitor</keyword>
</DOC>